Anti-Human C5 Recombinant Antibody (TAB-008)

Customer Review

There are currently no Customer reviews or questions for TAB-008. Click the button above to contact us or submit your feedback about this product.

Citations

1. Chen, Jin Y., et al. "Properdin is a key player in lysis of red blood cells and complement activation on endothelial cells in hemolytic anemias caused by complement dysregulation." Frontiers in immunology 11 (2020): 1460. https://doi.org/10.3389/fimmu.2020.01460
   This research investigates the crucial role of properdin in hemolytic anemias caused by complement dysregulation, specifically focusing on paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The study developed novel monoclonal antibodies against properdin and established in vitro models using PNH patient red blood cells and human primary endothelial cells. The findings demonstrate that properdin inhibition prevented hemolysis of PNH type II and III red blood cells more effectively than inhibition of Factor B, C3, or C5, with significantly lower molar IC90 values. Additionally, properdin plays a critical role in promoting complement activation on human endothelial cells exposed to heme and rH19-20, conditions that mimic what occurs in aHUS. Inhibition of properdin significantly reduced C3 fragment deposition on endothelial cells, suggesting therapeutic potential for complement-mediated diseases characterized by alternative pathway dysregulation.
   Creative Biolabs provided eculizumab, a critical complement inhibitor used as a reference standard throughout the study. This antibody helped establish a comparative benchmark against which the novel anti-properdin monoclonal antibodies could be evaluated. The availability of this well-characterized C5 inhibitor was essential for demonstrating the superior efficacy of properdin inhibition in protecting PNH red blood cells from complement-mediated lysis, particularly in situations where residual hemolysis persists despite eculizumab treatment. This comparison underscored the potential therapeutic value of targeting properdin in complement-mediated hemolytic anemias.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Eculizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Eculizumab.

Related Diseases

Systemic Lupus Erythematosus

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "C5"

Select a product category from the dropdown menu below to view related products.